Operating Income - Cartesian Therapeutics Inc (NASDAQ:RNAC) - Alpha Spread

Cartesian Therapeutics Inc
NASDAQ:RNAC

Watchlist Manager
Cartesian Therapeutics Inc Logo
Cartesian Therapeutics Inc
NASDAQ:RNAC
Watchlist
Price: 16.54 USD 5.82% Market Closed
Market Cap: 353.6m USD
Have any thoughts about
Cartesian Therapeutics Inc?
Write Note

Cartesian Therapeutics Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cartesian Therapeutics Inc
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Cartesian Therapeutics Inc
NASDAQ:RNAC
Operating Income
-$49m
CAGR 3-Years
-19%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Income
$16B
CAGR 3-Years
-1%
CAGR 5-Years
5%
CAGR 10-Years
10%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$10.3B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
0%
Amgen Inc
NASDAQ:AMGN
Operating Income
$6.2B
CAGR 3-Years
-11%
CAGR 5-Years
-9%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.2B
CAGR 3-Years
23%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
-14%
CAGR 5-Years
14%
CAGR 10-Years
17%

See Also

What is Cartesian Therapeutics Inc's Operating Income?
Operating Income
-49m USD

Based on the financial report for Jun 30, 2024, Cartesian Therapeutics Inc's Operating Income amounts to -49m USD.

What is Cartesian Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
3%

Over the last year, the Operating Income growth was -4%. The average annual Operating Income growth rates for Cartesian Therapeutics Inc have been -19% over the past three years , 3% over the past five years .

Back to Top